| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2023-051 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 第三届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）第三届董事会第五 次会议于 2023 年 8 月 28 日在公司会议室以现场方式召开，本次会议通知于 2023 年 8 月 18 日以电子邮件及电话方式送达全体董事。本次应出席董事 5 名， 实际出席会议的董事 5 名。本次会议由董事长张卫元先生主持，公司监事会成 员和高级管理人员列席了本次会议，会议的召集、召开和表决程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： （一）审议通过了《关于<2023 年半年度报告>及其摘要的议案》 公司董事会在全面审核公司《2023 年半年度报告》及其摘要后，一致认 为：公司 2 ...

武汉回盛生物科技股份有限公司 总经理工作细则 第一章 总则 第一条 为进一步完善武汉回盛生物科技股份有限公司（以下简称"公司"） 的治理结构和经营运作体系，促进经营管理的制度化、规范化、科学化，依照《中 华人民共和国公司法》（以下简称"《公司法》"）、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《武汉回盛生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，并结合公司实际情况，制定本 细则。 1、具备高度的敬业精神，全力履行好自己的职责，忠实地维护公司利益； 第二条 公司依法设置总经理和副总经理、财务总监、审计总监、人力资 源总监、技术服务总监、董事会秘书等高级管理人员（以下简称"高管"），高管 应当遵守法律、行政法规和《公司章程》的规定，履行诚信和勤勉的义务，高 管在就任时应签订《上市公司高级管理人员声明及承诺书》。总经理对公司董事 会负责并报告工作，副总经理、财务总监等高管对总经理负责并报告工作。在 总经理不能履行职权时，由董事长或董事长指定一名副总经理代行职权。 第二章 总经理的任免 第三条 总经理任职，应当具备下列条件： （一）个人品质：有较强的责任心，积 ...

证券代码：300871 证券简称：回盛生物 转债代码：123132 转债简称：回盛转债 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2023-003 特定对象调研 分析师会议 媒体采访 业绩说明会 投资者关系 新闻发布会 路演活动 活动类别 现场参观 其他（2023 年湖北辖区上市公司投资者网上集体接待日） 参与单位名称 通过全景路演网络平台参加 2023 年湖北辖区上市公司投资者网上集体接 待日活动的投资者 时 间 2023 年 5 月 25 日 14:30-16:35 地 点 全景网"投资者关系互动平台"（https://ir.p5w.net）网络文字互动 副总经理、财务总监 杨凯杰 董事会秘书 王庆峰 上市公司 接待人员姓名 公司就投资者在本次说明会中提出的问题进行了回复： 1、贵公司泰乐菌素生产开工率达到多少？ 回复：尊敬的投资者，您好！目前公司泰乐菌素生产线开工率 40% 多，正处于爬坡阶段。谢谢！ 投资者关系活动 2、公司宠物制剂产线终止，后续宠物药品生产是外代工吗？ 主要内容介绍 回复：尊敬的投资者，您好！目前公司子公司湖北回盛"片剂/颗粒 剂（含中药提取）"生产线已通过 GMP ...

证券代码：300871 证券简称：回盛生物 转债代码：123132 转债简称：回盛转债 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2023-002 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 参与单位名称 线上参与公司 2022 年度网上业绩说明会的全体投资者 时 间 2023 年 5 月 9 日 15:30-17:00 地 点 价值在线（https://www.ir-online.cn）网络互动 董事长、总经理 张卫元 | --- | |--------------------| | 独立董事 | | 副董事长 | | 副总经理、财务总监 | | 董事会秘书 | | 保荐代表人 | 上市公司 接待人员姓名 1、公司投资建设年产 2000 吨泰乐菌素、600 吨泰万菌素原料药项 目，是否存在产能消化问题？ 回复：原料-制剂一体化是公司根据行业发展趋势和自身竞争优势制 定的重要战略之一。泰乐菌素原料药是大环内酯类抗生素系列产品的重 要基础原料药，可最终应用于公司多个核心产品（如泰万菌素制剂、替 投资者关系活动 米考星制剂、泰地罗新制 ...

Financial Performance - In 2022, the company achieved operating revenue of 1,022.90 million CNY, a year-on-year increase of 2.68%, while net profit attributable to shareholders was 52.71 million CNY, a decrease of 60.33% compared to the previous year [3] - In Q4 2022, the company reported operating revenue of 351.42 million CNY, a year-on-year growth of 40.40% and a quarter-on-quarter increase of 28.04%. Net profit for the same period was 26.30 million CNY, showing a year-on-year increase of 100.21% and a quarter-on-quarter increase of 32.21% [3] - In Q1 2023, the company achieved operating revenue of 230.41 million CNY, a year-on-year increase of 12.03%, with net profit reaching 14.86 million CNY, a significant year-on-year growth of 634.03% [3] Product Development and Market Position - As of the end of 2022, the company had obtained 154 veterinary drug approval numbers, focusing on pig medications while also covering poultry, aquaculture, pets, and ruminants [4] - The company successfully launched a new antibiotic, "Taidiloxin Injection," which is a broad-spectrum, high-efficiency, and low-toxicity animal-specific antibacterial drug [4] - The company has made progress in its raw material and formulation integration strategy, achieving a revenue of 113 million CNY from raw materials, accounting for 11.11% of total revenue, with a year-on-year growth of 69% [3] Research and Development - By the end of 2022, the company had 113 R&D personnel, an increase of 12.71% year-on-year, and had made significant upgrades in hardware conditions and project management [4] - The company has 104 ongoing research projects and submitted five new veterinary drug registration applications to the Ministry of Agriculture and Rural Affairs [4] - The company is focusing on innovative drug development, with several new veterinary drugs in the pipeline, including a new drug for aquaculture that has completed toxicology trials [4] Challenges and Strategic Responses - The company faced challenges in 2022 due to a downturn in the pig farming industry, leading to weak demand for veterinary drugs and a decline in overall gross margin [5] - To enhance profitability, the company plans to improve customer coverage and penetration, leverage high-end technical services, and increase the sales proportion of high-margin products [5] - The company has expanded its client base, achieving coverage of the top 10 domestic pig farming enterprises and plans to strengthen communication with clients to enhance service and loyalty [5]

Business Focus - The company focuses on veterinary medicine, primarily in the pig medication sector, with sales revenue and operating profit mainly derived from this segment [5]. - The veterinary medicine industry is transitioning to a high-quality development stage, with increased focus on innovative and effective antimicrobial drugs [33]. - The scale of livestock farming in China has exceeded 70%, leading to increased concentration in the veterinary medicine industry [34]. - The company has established itself among the top 10 in the domestic pig breeding industry and maintains stable partnerships with numerous large-scale breeding enterprises [37]. - The company has obtained 154 veterinary drug approval numbers, with products widely used across various animal sectors including pigs, poultry, aquaculture, ruminants, and pets [38]. Financial Performance - The company's operating revenue for 2022 was ¥1,022,900,792.34, representing a 2.68% increase compared to ¥996,216,817.61 in 2021 [24]. - The net profit attributable to shareholders for 2022 was ¥52,706,475.48, a decrease of 60.33% from ¥132,865,534.22 in 2021 [24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,089,151.68, down 61.74% from ¥115,223,691.93 in 2021 [24]. - The net cash flow from operating activities decreased by 37.91% to ¥96,680,490.85 in 2022 from ¥155,718,489.99 in 2021 [24]. - The total assets at the end of 2022 were ¥2,989,114,303.25, an increase of 9.03% from ¥2,741,662,030.01 at the end of 2021 [24]. Risks and Challenges - The company faces risks from fluctuations in downstream industry demand, particularly in the pig breeding sector, which can impact overall demand for veterinary products [5]. - The company is exposed to risks from significant fluctuations in raw material prices, which directly affect the cost of veterinary drug formulations [6]. - The company has achieved certain success in controlling African swine fever, but any resurgence could negatively impact the pig breeding industry and, consequently, the demand for veterinary products [9]. Research and Development - The company is actively increasing R&D investment in pet medications and expanding market channels to tap into the pet medicine market [36]. - The company has completed the development of 10 new functional pet health products and submitted 10 national patent applications [74]. - The company has established a new independent R&D institution with a registered capital of CNY 10 million to enhance technological innovation [69]. - The company has established partnerships with academic institutions to enhance its research capabilities and drive technological advancements in its product lines [137]. Marketing and Sales Strategy - The marketing strategy has shifted from a "product-oriented" approach to a "value-oriented" approach, focusing on market pain points and improving breeding efficiency [53]. - The company has implemented a production management model combining sales-based production and safety stock, ensuring adequate supply for high-demand products [45]. - The company has adopted a direct sales and distribution model, signing annual cooperation agreements with both large-scale breeding groups and small-scale farmers [45]. Governance and Compliance - The company’s financial report has been verified for accuracy and completeness by its board and management, ensuring transparency for investors [3]. - The governance structure includes a complete system with a general meeting of shareholders, board of directors, supervisory board, and management team, ensuring clear functional roles [128]. - The company has not reported any significant discrepancies in governance compared to legal and regulatory requirements [121]. - The company has a dedicated investor relations section on its official website to maintain good communication with investors [121]. Employee and Management - The total number of employees at the end of the reporting period is 957, with 336 in the parent company and 621 in major subsidiaries [155]. - The company has a strong emphasis on performance-based remuneration for its senior management [144]. - The company has implemented a stock incentive plan to align the interests of management with those of shareholders, which includes the repurchase and cancellation of shares [133]. Environmental and Social Responsibility - The company has actively responded to national carbon peak and carbon neutrality initiatives by optimizing processes to reduce energy consumption and utilizing rooftop resources for photovoltaic power generation [176]. - The company emphasizes strict compliance with environmental regulations and has implemented measures to reduce resource consumption and environmental impact during production [182]. - The company has not engaged in any significant environmental violations or received administrative penalties during the reporting period [176]. Future Outlook - The company aims to achieve breakthroughs in poultry, ruminants, and aquaculture while consolidating its advantages in pig medications [36]. - The company plans to enhance its R&D capabilities, focusing on traditional Chinese veterinary medicine and biological veterinary medicine, to develop new drugs with its own branding [111]. - The company anticipates a gradual recovery in market conditions, projecting improved financial performance in the upcoming fiscal year [136].

Financial Performance - The company's revenue for Q1 2023 was CNY 230,412,076.04, representing a 12.03% increase compared to CNY 205,665,754.61 in the same period last year[6] - Net profit attributable to shareholders reached CNY 14,855,718.00, a significant increase of 634.03% from CNY 2,023,854.94 in the previous year[6] - The net profit after deducting non-recurring gains and losses was CNY 8,945,243.79, up 697.11% from CNY 1,122,203.66 year-on-year[6] - Basic and diluted earnings per share were both CNY 0.09, an increase of 800% compared to CNY 0.01 in the same period last year[6] - Total operating revenue for Q1 2023 was 16,631,467.48, a significant increase from 2,793,791.45 in Q1 2022, representing a growth of approximately 496%[26] - Net profit for Q1 2023 reached 14,855,718.00, compared to 2,023,854.94 in the same period last year, marking a year-over-year increase of about 634%[26] - Basic and diluted earnings per share for Q1 2023 were both 0.09, up from 0.01 in Q1 2022, indicating a substantial improvement in profitability[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,024,445,118.45, a 1.18% increase from CNY 2,989,114,303.25 at the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 3,024,445,118.45, up from CNY 2,989,114,303.25 at the beginning of the year, reflecting a growth of 1.2%[22] - The total current assets reached CNY 1,368,615,054.54, compared to CNY 1,351,475,288.90 at the start of the year, indicating an increase of 1.9%[20] - The total liabilities as of March 31, 2023, were CNY 1,468,156,374.06, slightly up from CNY 1,447,682,082.36 at the beginning of the year, showing an increase of 1.4%[22] - The total non-current assets were CNY 1,655,830,063.91, up from CNY 1,637,639,014.35, reflecting a growth of 1.1%[20] - Short-term borrowings rose to CNY 257,017,934.21 from CNY 220,084,829.04, an increase of 16.8%[21] - The company's retained earnings increased to CNY 391,076,854.19 from CNY 376,221,136.19, a growth of 3.9%[22] - The total equity attributable to the owners of the parent company was CNY 1,556,288,744.39, compared to CNY 1,541,432,220.89 at the beginning of the year, indicating an increase of 1.0%[22] Cash Flow - The company's cash flow from operating activities was negative at CNY -17,180,234.31, slightly worse than CNY -16,025,127.81 in the same period last year, reflecting a decrease of 7.21%[6] - Cash flow from operating activities showed a net outflow of -17,180,234.31, slightly worse than the -16,025,127.81 recorded in Q1 2022[29] - The net cash flow from investing activities improved by 76.49%, amounting to CNY -88,514,280.15 compared to CNY -376,449,232.15 in the previous year[14] - Cash flow from investing activities resulted in a net outflow of -88,514,280.15, compared to -376,449,232.15 in the previous year, indicating a reduction in cash burn[29] - The net cash flow from financing activities surged by 4,596.57% to CNY 64,595,118.87, primarily due to increased borrowings[14] - Cash flow from financing activities generated a net inflow of 64,595,118.87, a significant increase from 1,375,366.95 in Q1 2022, reflecting improved financing conditions[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,202, with the largest shareholder holding 49.86% of the shares[15] Government Subsidies - The company received government subsidies totaling CNY 3,980,605.72 during the reporting period, contributing to its financial performance[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were 220,505,096.35, up from 201,486,255.25 in Q1 2022, indicating a rise of approximately 9.5%[25] - Research and development expenses for Q1 2023 were 9,286,444.32, slightly down from 9,754,406.16 in Q1 2022, showing a focus on cost management in R&D[25] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 395,545,161.51 from CNY 424,044,443.62, representing a decline of 6.1%[19] - The company reported a total cash and cash equivalents balance of 237,472,437.22 at the end of Q1 2023, down from 575,070,614.85 at the end of Q1 2022[30] - The company received cash inflows from investment activities totaling 352,273,935.15, a significant increase from 30,353,258.20 in the previous year, indicating strong investment recovery[29]

证券代码：300871 证券简称：回盛生物 公告编号：2023-034 武汉回盛生物科技股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 武汉回盛生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司 定于 2023 年 05 月 09 日（星期二）15:30-17:00 在"价值在线"（www.ir- online.cn）举办武汉回盛生物科技股份有限公司 2022 年度业绩说明会，与投 会议召开时间：2023 年 5 月 9 日（星期二）15:30-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2023 年 5 月 9 日前访问网址 https://eseb.cn/144ZHWhBtzG 或使用微信扫描下方小程序码进行会 前提问，公司将通过本次业 ...

证券代码：300871 证券简称：回盛生物 1 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | --- | |-------------------------|-------|-----------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：300871 证券简称：回盛生物 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------|--------------------------------------------------------------|----------------------|------------------------------------------------------------|----------|---------| | 投资者关系 \n活动类别 | | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n现场参观 \n广发证券 | \n \n \n \n周舒玥 | □分析师会议 \n 业绩说明会 \n□路演活动 \n 其他 \n长江证券 | 电话会议 | 高辰星 | | | | 中信证券 | 彭家乐 | 长江证券 | | 顾熀乾 | | | | 中信证券 | 罗 寅 | 华宝基金 | | 陆 恒 | | | | 中信证券 ...